ChemicalBook > Product Catalog >API >Digestive system drugs >Liver Disease drugs >Nedosiran Sodium

Nedosiran Sodium

Nedosiran Sodium Suppliers list
Company Name: BOC Sciences
Tel: +1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:Nedosiran sodium
CAS:2247026-22-6
Purity:98% Package:0.5 mg Remarks:Please reach out to us for more information about custom solutions.
Company Name: Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel: +86-0086-13720134139
Email: orders@jknbiochem.com
Products Intro: Product Name:Nedosiran Sodium
CAS:2247026-22-6
Purity:0.98 Package:10G:100G
Company Name: Chongqing jooe co., ltd
Tel: +86-15223382610
Email: info@jooe.com
Products Intro: Product Name:Nedosiran sodium
CAS:2247026-22-6
Purity:0.99 Package:1kg,5kg,25kg
Company Name: Wuhan Jingkangen Biomedical Technology Co., Ltd  
Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Products Intro: Product Name:Nedosiran Sodium
CAS:2247026-22-6
Purity:98% Package:1G:5G
Company Name: Olix ( Hubei) Pharmaceutical Technology Co., Ltd  
Tel: 17316404525 17316404525
Email: 209533805@qq.com
Products Intro: Product Name:Nedosiran Sodium
CAS:2247026-22-6
Purity:98% HPLC Package:5mg,500mg,1g,100g
Nedosiran Sodium Basic information
Product Name:Nedosiran Sodium
Synonyms:Nedosiran Sodium;Hexanamide, N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]- (ACI)
CAS:2247026-22-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Nedosiran Sodium Structure
Nedosiran Sodium Chemical Properties
form Solid
color White to off-white
Safety Information
MSDS Information
Nedosiran Sodium Usage And Synthesis
UsesNedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate[1][2][3].
in vivo

Nedosiran sodium is a RNAi therapy for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase[3].
Nedosiran sodium specially inhibits hepatic expression of lactate dehydrogenase (LDHA)[3].
Nedosiran sodium is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran sodium is administered by monthly subcutaneous injection. Nedosiran sodium decreases plasma oxalate in animal models[3].

References[1] Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149. DOI:10.1016/j.urology.2021.03.014
[2] Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep.2021 Feb 3;6(4):1088-1098. DOI:10.1016/j.ekir.2021.01.029
[3] Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol.2021 May 22. DOI:10.1111/bcp.14925
Nedosiran Sodium Preparation Products And Raw materials
Tag:Nedosiran Sodium(2247026-22-6) Related Product Information
ALN-G01 FX-11 Linalyl acetate SAR439774 Givosiran sodium siRNA negative control